Company Analysis

Celldex Therapeutics, Inc. (CLDX)

Nasdaq: CLDX · In Vitro & In Vivo Diagnostic Substances · Hampton, NJ · filing with the SEC since 1995
Grade5.1
◀ Past 3.8● Present 6.0▶ Future 5.1
1 est.

The company now

Celldex Therapeutics, Inc. is classed by the SEC under In Vitro & In Vivo Diagnostic Substances (industry code 2835), based in Hampton, NJ. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $1.5 million and a loss of $259 million (its filed statements).

From its filings and filed figures; the desk's account of it is not written yet.

Where the revenue comes from

fiscal 2025, as filed

Revenue by product, fiscal 2025

ProductFiscal 2025Fiscal 2024Share of revenue
Grant$1.4M$7.0M93.7%
Service$97,000$13,0006.3%

As tagged in its annual report (Form 10-K, filed Feb 25, 2026 ↗), read from the SEC's financial statement data sets. The year before is the figure the record holds for the prior fiscal year.

The desk's written account of this company, its Past, Present and Future, is not on file yet.

How the company works

The desk has not read this company's annual report yet.

The record in brief

The desk has not written this company's report yet.

SI Assistanton CLDX · research, not advice